An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study)
about
Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trialA phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)Human parvovirus 4 'PARV4' remains elusive despite a decade of studyHIV-1 Vaccine Trials: Evolving Concepts and DesignsHIV-1 vaccines: challenges and new perspectivesNovel directions in HIV-1 vaccines revealed from clinical trialsNonreplicating vectors in HIV vaccines.Functional avidity and IL-2/perforin production is linked to the emergence of mutations within HLA-B*5701-restricted epitopes and HIV-1 disease progressionAdvancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.Comparison of two high-throughput assays for quantification of adenovirus type 5 neutralizing antibodies in a population of donors in China.MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load.Challenges in the design of a T cell vaccine in the context of HIV-1 diversity.CD154 and IL-2 signaling of CD4+ T cells play a critical role in multiple phases of CD8+ CTL responses following adenovirus vaccination.Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen.HLA-B*57 Micropolymorphism shapes HLA allele-specific epitope immunogenicity, selection pressure, and HIV immune controlImmune-mediated attenuation of HIV-1Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaA trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challengeHLA-C and HIV-1: friends or foes?New prospects for a preventive HIV-1 vaccine.Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in miceLower Viral Loads and Slower CD4+ T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection.Immunotherapies to prevent mother-to-child transmission of HIVToll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques.Novel HIV vaccine strategies: overview and perspective.Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors.Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.Complex immune correlates of protection in HIV-1 vaccine efficacy trials.System pharmacogenomics application in infectious diseases.Can research at the end of life be a useful tool to advance HIV cure?From empiricism to rational design: a personal perspective of the evolution of vaccine development.A 2020 vision for vaccines against HIV, tuberculosis and malaria.
P2860
Q28730828-78151CEE-D8ED-49E7-871A-836BB6DAEDF9Q28741673-96DA65BF-579E-488E-BDCC-7D9AEF91CAE3Q30238496-D50D65E9-2DE0-4C78-AE30-B9F8E749B654Q30425520-DD4C172E-CF74-4B7A-9809-ED4D3AFDA6DDQ33577972-4D2142BD-080E-41F4-BDC7-7EFBD9983940Q33645528-B8DD8708-B348-4312-94C1-46B12AD07F7CQ33693891-CED415AD-97BA-4A62-8274-5524852BCEBCQ33712891-056D629F-28C7-411D-B361-2ECE9F939C4CQ33742529-982D40D8-653D-4F67-BFAA-E3092A0D5D92Q34289005-76B55112-77D1-4F9E-96E6-E8BFB57D3742Q34405131-69C9285E-AA62-43C3-B4A6-471C67CA3854Q34423446-CCFB51AB-DFC8-4F7E-93E6-6279C2EE0544Q34447762-80E48865-06DD-40F6-92E6-86C9F07513AAQ35160124-A9113D10-E5C4-41D8-8FC7-4DAEF36FAA99Q35192726-3A3A9C37-CAA2-47DD-B296-3CBCB25D103EQ35665876-E4A6C59E-CC3E-4C97-8AAD-69A6090D0C62Q35798108-5B38D9B2-E9ED-4F14-A994-BB3523610E65Q35826525-E9EC1D43-3515-4E56-8F6C-449AF643942BQ36024470-FB64E3FB-9DC3-4F07-AEBE-0D31772D176EQ36066058-07425503-21F4-4242-B354-0AFDB81BFC82Q36223864-045A9BC7-7285-47D5-937A-5A019CD59AF9Q36376210-31C8896E-B647-4339-9D44-90BC84EF899FQ36890963-A95D04AF-0871-4804-A2EE-CB9C38CC5636Q37074610-965658C0-24B3-4A74-9067-8CE95144DD0DQ37187509-613E1655-C61F-4740-9839-89833BF72F94Q37316629-03BF3B13-2352-4B4F-825B-458354162960Q37643792-1C0716F5-9052-499D-9FEA-4E8F65B21750Q37668399-EDFEDD7C-60AF-4E3F-B8EF-53D61F7FD12CQ37932525-ECE64FD7-BCC2-46CD-AD27-C6029D449E3DQ38096490-EEA25100-5B5A-4AD9-80D2-AD25826687CEQ39108779-EE9F2E60-687A-453E-B3A1-0F7F6B5F867DQ40267857-E886FEDF-E848-4E57-A76E-6C2ED7678760Q46512061-F10A3EB2-19B4-4283-8096-4469FBFF5305Q47633699-C66ED784-4E9E-40ED-BE7C-B252EB4F6800Q47980915-08DAF192-9549-4A52-992D-EB516071F1D6
P2860
An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study)
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
An Ad5-vectored HIV-1 vaccine ...... trolled trial (the Step study)
@ast
An Ad5-vectored HIV-1 vaccine ...... trolled trial (the Step study)
@en
type
label
An Ad5-vectored HIV-1 vaccine ...... trolled trial (the Step study)
@ast
An Ad5-vectored HIV-1 vaccine ...... trolled trial (the Step study)
@en
prefLabel
An Ad5-vectored HIV-1 vaccine ...... trolled trial (the Step study)
@ast
An Ad5-vectored HIV-1 vaccine ...... trolled trial (the Step study)
@en
P2093
P2860
P356
P1476
An Ad5-vectored HIV-1 vaccine ...... trolled trial (the Step study)
@en
P2093
D Mehrotra
D W Fitzgerald
M Robertson
Step Study Protocol Team
P2860
P304
P356
10.1093/INFDIS/JIQ114
P407
P577
2011-03-01T00:00:00Z